Mutant herpes simplex virus-2 for cancer therapy
US10039796B2 · kind B2 · utility
11Cited by
2References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 13, 2015 |
| Grant date | Aug 7, 2018 |
| Priority date | — |
| Expiry date | Nov 10, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2810/60
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to the composition and use of a modified Herpes Simplex Virus Type 2 (HSV-2) as a medicament in the treatment of cancer. The modified HSV-2 has fusogenic activity, and comprises a modified/mutated ICP10 polynucleotide encoding a polypeptide having ribonucleotide reductase activity and lacking protein kinase activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.